

# CANCER AND BLOOD



01

[Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry.](#)

**Abadir E, Othman J, Kwan J, Gottlieb DJ, Kennedy GA, Bajel A, Doocey R, Perera T, Watson AM, Bardy PG, Greenwood M, Curtis DJ, Tran S, Moore J, Hamad N.**

Transplant Cell Ther. 2023 Nov 27:S2666-6367(23)01707-4. doi: 10.1016/j.jtct.2023.11.018.  
Online ahead of print.

02

[Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer \(TALAPRO-2\): a randomised, placebo-controlled, phase 3 trial.](#)

**Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Fizazi K.**

Lancet. 2023 Jul 22;402(10398):291-303.

03

[Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.](#)

**Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, McDermott R, Sala-Gonzalez N, Fong PC, Greil R, Retz M, Sade JP, Yanez P, Huang YH, Begbie SD, Gafanov RA, De Santis M, Rosenbaum E, Kolinsky MP, Rey F, Chiu KY, Roubaud G, Kramer G, Sumitomo M, Massari F, Suzuki H, Qiu P, Zhang J, Kim J, Poehlein CH, Yu EY.**

J Clin Oncol. 2023 Aug 1;41(22):3839-3850. doi: 10.1200/JCO.23.00233.

04

[The association of socioeconomic deprivation with access and survival after hematopoietic stem cell transplantation in New Zealand.](#)

**Belyaev AM, Lewis C, Doocey R, Bergin CJ.**

Asia Pac J Clin Oncol. 2023 Apr;19(2):e89-e95. doi: 10.1111/ajco.13797.

# CANCER AND BLOOD



05

[An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles.](#)

Bresalier RS, Senore C, Young GP, Allison J, Benamouzig R, Benton S, Bossuyt PMM, Caro L, Carvalho B, Chiu HM, Coupé VMH, de Klaver W, de Klerk CM, Dekker E, Dolwani S, Fraser CG, Grady W, Guittet L, Gupta S, Halloran SP, Haug U, Hoff G, Itzkowitz S, Kortlever T, Koulaouzidis A, Ladabaum U, Lauby-Secretan B, Leja M, Levin B, Levin TR, Macrae F, Meijer GA, Melson J, O'Morain C, Parry S, Rabeneck L, Ransohoff DF, Sáenz R, Saito H, Sanduleanu-Dascalescu S, Schoen RE, Selby K, Singh H, Steele RJC, Sung JJY, Symonds EL, Winawer SJ; Members of the World Endoscopy Colorectal Cancer Screening New Test Evaluation Expert Working Group.

Gut. 2023 Oct;72(10):1904-1918. doi: 10.1136/gutjnl-2023-329701.

06

[False positive Hb Bart's immunochromatographic strip test for alpha thalassaemia in delta-beta thalassaemia carriers.](#)

Chan G, Wong J, Tan T, Ghallyan N, Browett P.

Int J Lab Hematol. 2023 Dec;45(6):984-986. doi: 10.1111/ijlh.14122. Epub 2023 Jun 14.

07

[Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease and Treatment with Defibrotide in Allogeneic Transplantation: A Multicenter Australasian Registry Study.](#)

Coutsouvelis J, Kirkpatrick CM, Dooley M, Spencer A, Kennedy G, Chau M, Huang G, Doocey R, Copeland TS, Do L, Bardy P, Kerridge I, Cole T, Fraser C, Perera T, Larsen SR, Mason K, O'Brien TA, Shaw PJ, Teague L, Butler A, Watson AM, Ramachandran S, Marsh J, Khan Z, Hamad N.

Transplant Cell Ther. 2023 Mar 18:S2666-6367(23)01173-9. doi: 10.1016/j.jtct.2023.03.014.

Online ahead of print.

08

[A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.](#)

Desai J, Fong P, Moreno V, Frentzas S, Meniawy T, Markman B, Voskoboynik M, Rahman T, Budha N, Wu J, Marlow J, Yang S, Calvo E, Martin-Liberal J.

Br J Cancer. 2023 Apr;128(8):1418-1428. doi: 10.1038/s41416-022-02128-3.

# CANCER AND BLOOD



09

[The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance.](#)

**Di Ciaccio PR, Mills G, Shipton MJ, Campbell B, Gregory G, Langfield J, Greenwood M, McKeague S, Shanavas M, Eslick R, Kidson-Gerber G, Smallbone P, Tang C, Morris K, Bilmon I, Yannakou CK, Badoux X, Berkahn L, Farina S, Mason KD, Motum P, Goss K, Hamad N.**

Br J Haematol. 2023 Jun;201(5):887-896. doi: 10.1111/bjh.18727. Epub 2023 Mar 7.

10

[Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy.](#)

**Fitzgerald S, Blenkinsop C, Stephens R, Mathy JA, Somers-Edgar T, Rolfe G, Martin R, Jackson C, Eccles M, Robb T, Rodger E, Lawrence B, Guilford P, Lasham A, Print CG.**

Mol Diagn Ther. 2023 Apr 26;1:14. doi: 10.1007/s40291-023-00651-4.

11

[First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.](#)

**Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N.**

Nat Med. 2023 Dec 4. doi: 10.1038/s41591-023-02704-x. Online ahead of print.

12

[Bilateral Neck Irradiation: A Regional Cancer Experience in New Zealand.](#)

**Fong SC, Pandey R, Rajaretnam M, Delaibatiki M, Peel DNY.**

J Med Radiat Sci. 2023 Sep;70(3):292-300.

13

[Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.](#)

**Friedlander M, Mileskin L, Lombard J, Frenzas S, Gao B, Wilson M, Meniawy T, Baron-Hay S, Briscoe K, McCarthy N, Fountzilas C, Cervantes A, Ge R, Wu J, Spira A.**

Br J Cancer. 2023 Sep;129(5):797-810.

14

[Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy.](#)

**Furkert C, Martin R, Sharma A, Rivalland G.**

World J Surg Oncol. 2023 Sep 15;21(1):291.

# CANCER AND BLOOD



15

Stability of trastuzumab during nanomedicine formulation using SEC-HPLC coupled with polyacrylamide gel electrophoresis.

**Gao Y, Shelling AN, Porter D, Leung E, Wu Z.**

Pharm Dev Technol. 2023 Mar-Apr;28(3-4):288-298. doi: 10.1080/10837450.2023.2191277.

16

Real-world decision-making in the management of patients presenting with major bleeding on rivaroxaban: the Auckland regional experience.

**Grainger BT, Merriman E, Royle G, Eaddy N, Ockelford P, Young**

Intern Med J. 2023 Aug;53(8):1444-1449. doi: 10.1111/imj.15786.

17

Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.

**Grivas P, Kopyltsov E, Su PJ, Parnis FX, Park SH, Yamamoto Y, Fong PC, Tournigand C, Climent Duran MA, Bamias A, Caserta C, Chang J, Cislo P, di Pietro A, Wang J, Powles T.**

Eur Urol. 2023 Apr;83(4):320-328. doi: 10.1016/j.eururo.2022.04.016. Epub 2022 May 30.

18

ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.

**Hamad N, Bilmon I, Chee L, Henden A, Johnston A, Purtill D, Bajel A, Tey SK, Yeung D, Cole T, Lewis C, Butler J.**

Intern Med J. 2023 Nov 28. doi: 10.1111/imj.16255. Online ahead of print.

19

Sporadic Metastatic Malignant Peripheral Nerve Sheath Tumour with an NF1 Mutation Responding to Trametinib: A Case Report.

**Hitchen N, Cross M, Laking G, Connor J, Korenbaum C.**

Case Rep Oncol. 2023 Jan 12;16(1):1-6. doi: 10.1159/000528743.

20

Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.

**Hitchen N, Waldron NR, Deva S, Findlay M, Lawrence B.**

Asia Pac J Clin Oncol. 2023 Oct;19(5):e231-e238. doi: 10.1111/ajco.13845.

# CANCER AND BLOOD



21

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.

Holmes FA, Moy B, Delaloge S, Chia SKL, Ejlertsen B, Mansi J, Iwata H, Gnant M, Buyse M, Barrios CH, Silovski T, Šeparović R, Bashford A, Zotano AG, Denduluri N, Patt D, Gokmen E, Gore I, Smith JW 2nd, Loibl S, Masuda N, Tomašević Z, Petráková K, DiPrimeo D, Wong A, Martin M, Chan A; ExteNET Study Group.

Eur J Cancer. 2023 May;184:48-59. doi: 10.1016/j.ejca.2023.02.002.

22

Classic Hodgkin lymphoma.

Kahn J, Dabaja B, Wu S, Kelly K, Berkahn L, Pavlovsky A, Sureda A, LaCasce A.

Hematol Oncol. 2023 Dec 1. doi: 10.1002/hon.3239. Online ahead of print.

23

Quality outcomes for end-of-life care among people with haematological malignancies at a New Zealand cancer centre.

Kim A, O'Callaghan A, Hemmaway C, Johney L, Ho J.

Intern Med J. 2023 Sep 17. doi: 10.1111/imj.16235.

24

The role of radiation therapy in the management of primary retroperitoneal sarcoma: A systematic review and clinical practice guidelines from the Australia and New Zealand Sarcoma Association.

Lawless A, Zhou DD, McDonough J, Lo H, Mar J, Lazarakis S, Ward I, Connor J, Thompson SR, Coker D, Johnston A, Gyorki DE, Hong AM.

Cancer Treat Rev. 2023 Nov;120:102620. doi: 10.1016/j.ctrv.2023.102620. Epub 2023 Aug 28.

25

Sporadic Metastatic Malignant Peripheral Nerve Sheath Tumour with an NF1 Mutation Responding to Trametinib: A Case Report.

Hitchen N, Cross M, Laking G, Connor J, Korenbaum C.

Case Rep Oncol. 2023 Jan 12;16(1):1-6. doi: 10.1159/000528743.

26

Dosimetric benefits of 3D-printed modulated electron bolus following lumpectomy and whole-breast radiotherapy for left breast cancer.

Lee VWY, Liu ACH, Cheng KW, Chiang CL, Lee VH.

Med Dosim. 2023 Spring;48(1):37-43. doi: 10.1016/j.meddos.2022.10.001.

# CANCER AND BLOOD



27

[Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy.](#)

Li M, Chan DL, Tapia Rico G, Cehic G, Lawrence B, Wylid D, Pattison DA, Kong G, Hicks R, Michael M, Kiberu AD, Lim J, Clifton-Bligh R, Tsang V, Roach PJ, Leyden J, Diakos CI, Price TJ, Pavlakis N. *Neuroendocrinology*. 2023;113(3):281-288. doi: 10.1159/000526848. Epub 2022 Sep 1

28

[Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group.](#)

Loong HH, Shimizu T, Prawira A, Tan AC, Tran B, Day D, Tan DSP, Ting FIL, Chiu JW, Hui M, Wilson MK, Prasongsook N, Koyama T, Reungwetwattana T, Tan TJ, Heong V, Voon PJ, Park S, Tan IB, Chan SL, Tan DSW. *ESMO Open*. 2023 Aug;8(4):101586. doi: 10.1016/j.esmooop.2023.101586.

29

[Patient-Reported Symptom Severity, Health-Related Quality of Life, and Emotional Distress Trajectories During and After Radiation Therapy for Human Papillomavirus-Associated Oropharyngeal Cancer: A TROG 12.01 Secondary Analysis.](#)

McDowell L, Bressel M, King MT, Corry J, Kenny L, Porceddu S, Wratten C, Macann A, Jackson JE, Rischin D. *Int J Radiat Oncol Biol Phys*. 2023 Mar 1;S0360-3016(23)00199-2. doi: 10.1016/j.ijrobp.2023.02.041.

30

[Patient- and Clinician-Reported Outcomes in Human Papillomavirus-Associated Tonsillar Carcinoma Treated With Unilateral and Bilateral Intensity Modulated Radiation Therapy-A Substudy From TROG 12.01.](#)

McDowell L, Rischin D, King M, Kenny L, Porceddu S, Wratten C, Macann A, Jackson JE, Bressel M, Fua T, Lin C, Liu C, Corry J. *Int J Radiat Oncol Biol Phys*. 2023 Jan 1;115(1):174-188. doi: 10.1016/j.ijrobp.2022.08.006.

31

[Patient-Reported Bowel, Urinary, and Sexual Outcomes After Laparoscopic-Assisted Resection or Open Resection for Rectal Cancer: The Australasian Laparoscopic Cancer of the Rectum Randomized Clinical Trial \(ALaCart\).](#)

Mercieca-Bebber R, Eggins R, Brown K, GebSKI VJ, Brewer K, Lai L, Bailey L, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Wilson K, Hague W, Hayes J, White S, Morgan M, Simes RJ, Stevenson ARL. *Ann Surg*. 2023 Mar 1;277(3):449-455. doi: 10.1097/SLA.0000000000005412.

32

[Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone \(OUTBACK\): an international, open-label, randomised, phase 3 trial.](#)

Mileshkin LR, Moore KN, Barnes EH, GebSKI V, Narayan K, King MT, Bradshaw N, Lee YC, Diamante K, Fyles AW, Small W Jr, Gaffney DK, Khaw P, Brooks S, Thompson JS, Huh WK, Mathews CA, Buck M, Suder A, Lad TE, Barani IJ, Holschneider CH, Van Dyk S, Quinn M, Rischin D, Monk BJ, Stockler MR. *Lancet Oncol*. 2023 May;24(5):468-482. doi: 10.1016/S1470-2045(23)00147-X.

# CANCER AND BLOOD



33

## U-Net Architecture for Prostate Segmentation: The Impact of Loss Function on System Performance.

**Montazerolghaem M, Sun Y, Sasso G, Haworth A.**

Bioengineering (Basel). 2023 Mar 26;10(4):412. doi: 10.3390/bioengineering10040412.

34

## Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry.

**Nguyen J, Wellard C, Chung E, Cheah CY, Dickinson M, Doo NW, Keane C, Talaulikar D, Berkahn L, Morgan S, Hamad N, Cochrane T, Johnston AM, Forsyth C, Opat S, Barraclough A, Mutsando H, Ratnasingam S, Giri P, Wood EM, McQuilten ZK, Hawkes EA; Lymphoma and Related Diseases Registry investigators.**

Eur J Haematol. 2023 Apr;110(4):386-395. doi: 10.1111/ejh.13915.

35

## Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.

**Opat S, Tedeschi A, Hu B, Linton KM, McKay P, Leitch S, Coleman M, Zinzani PL, Jin J, Sun M, Sobieraj-Teague M, Browett P, Ke X, Thieblemont C, Ardeshta K, Bijou F, Walker P, Hawkes EA, Ho SJ, Zhou K, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J.**

Blood Adv. 2023 Nov 28;7(22):6801-6811. doi: 10.1182/bloodadvances.2023010668.

36

## Palliative radiotherapy is effective for both well- and poorly differentiated neuroendocrine neoplasms.

**O'Reilly E, Lao L, Woodhouse B, Sharples K, Print C, Lawrence B.**

J Med Imaging Radiat Oncol. 2023 Oct 29. doi: 10.1111/1754-9485.13597.

37

## Allogeneic haemopoietic cell transplant services in Australia and New Zealand in the first year of the COVID-19 pandemic: a report from Australia and New Zealand transplant and cellular therapies.

**Othman J, Aarons D, Bajel A, Butler J, Doocey R, O'Brien T, Purtill D, Smith L, Wilcox L, Hamad N.**

Intern Med J. 2023 Mar;53(3):323-329. doi: 10.1111/imj.15886.

38

## A Randomised Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial.

**Othman J, Wilhelm-Benartzi CS, Dillon R, Knapper S, Freeman SD, Batten LM, Canham J, Hinson EL, Wych J, Betteridge S, Villiers W, Kleeman M, Gilkes AF, Potter N, Overgaard U, Mehta P, Kottaridis P, Cavenagh J, Hemmaway CJ, Arnold C, Dennis M, Russell NH.**

Blood Adv. 2023 May 12;bloodadvances.2023010276. doi: 10.1182/bloodadvances.2023010276.

# CANCER AND BLOOD



39

Utilizing clinical, pathological and radiological information to guide postoperative radiotherapy in prostate cancer.

**Padayachee J, Chaudhary S, Shim B, So J, Lim R, Raman S.**

Expert Rev Anticancer Ther. 2023 Mar;23(3):293-305. doi: 10.1080/14737140.2023.2181795.

40

Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.

**Perram J, Purtil D, Bajel A, Butler J, O'Brien T, Teh B, Gilroy N, Ho PJ, Doocey R, Hills T, Perera T, Douglas G, Ramachandran S, Chee L, Trotman J, Weinkove R, Keogh S, Fraser C, Cochrane T, Watson AM, Diamond P, Latimer M, Irving I, Blyth E, Cheah C, Cole T, Milliken S, Yang H, Greenwood M, Bardy P, Kennedy G, Larsen S, Conyers R, Hamad N.**

Intern Med J. 2023 Jan;53(1):119-125. doi: 10.1111/imj.15978.

41

Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.

**Reck M, Barlesi F, Yang JC, Westeel V, Felip E, Özgüroğlu M, Dols MC, Sullivan R, Kowalski DM, Andric Z, Lee DH, Sezer A, Hu P, Wang X, von Heydebreck A, Jacob N, Mehr KT, Park K. J**

J Thorac Oncol. 2023 Sep 24:S1556-0864(23)02250-5. doi: 10.1016/j.jtho.2023.09.1445

42

Complex Patterns of Genomic Heterogeneity Identified in 42 Tumor Samples and ctDNA of a Pulmonary Atypical Carcinoid Patient.

**Robb TJ, Tsai P, Fitzgerald S, Shields P, Houseman PS, Patel R, Fan V, Curran B, Tse R, Ting J, Kramer N, Woodhouse BJ, Coats E, Le Quesne Stabej P, Reeve J, Parker K, Lawrence B, Blenkiron C, Print CG.**

Cancer Res Commun. 2023 Jan 10;3(1):31-42. doi: 10.1158/2767-9764.CRC-22-0101.

43

Chromosomal Aberrations Accumulate during Metastasis of Virus-Negative Merkel Cell Carcinoma.

**Robb TJ, Ward Z, Houseman P, Woodhouse B, Patel R, Fitzgerald S, Tsai P, Lawrence B, Parker K, Print CG, Blenkiron C.**

J Invest Dermatol. 2023 Feb 1:S0022-202X(23)00069-6. doi: 10.1016/j.jid.2023.01.015.

44

Key performance indicators for improving outcomes from retroperitoneal sarcoma surgery in New Zealand.

**Russell M, Burnett T, Mackay G, Cranshaw I.**

ANZ J Surg. 2023 Mar;93(3):585-589. doi: 10.1111/ans.18321.

# CANCER AND BLOOD



45

[Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases.](#)

**Siva S, Sakyanun P, Mai T, Wong W, Lim A, Ludbrook J, Bettington C, Rezo A, Pryor D, Hardcastle N, Kron T, Higgs B, Le H, Skala M, Gill S, Eade T, Awad R, Sasso G, Vinod S, Montgomery R, Ball D, Bressel M.**

J Clin Oncol. 2023 May 14;JCO2300150. doi: 10.1200/JCO.23.00150. Online ahead of print.

46

[Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer \(ENZAMET\): an international, open-label, randomised, phase 3 trial.](#)

**Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group.**

Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3.

47

[Raman spectroscopy system for real-time diagnosis of clinically significant prostate cancer tissue.](#)

**van Breugel SJ, Low I, Christie ML, Pokorny MR, Nagarajan R, Holtkamp HU, Srinivasa K, Amirapu S, Nieuwoudt MK, Simpson MC, Zargar-Shoshtari K, Aguergaray C.**

J Biophotonics. 2023 May;16(5):e202200334. doi: 10.1002/jbio.202200334. Epub 2023 Feb 12.

48

[Treatment outcomes of adult acute lymphoblastic leukaemia in Auckland, New Zealand.](#)

**Wong SHC, Offner M, Hu R, Hemmaway C.**

NZ Med J. 2023 Mar 24;136(1572):10-18.

49

[Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.](#)

**Yu EY, Piulats JM, Gravis G, Fong PCC, Todenhöfer T, Laguerre B, Arranz JA, Oudard S, Massard C, Heinzlbecker J, Nordquist LT, Carles J, Kolinsky MP, Augustin M, Gurney H, Tafreshi A, Li XT, Qiu P, Poehlein CH, Schloss C, de Bono JS.**

Eur Urol. 2023 Jan;83(1):15-26. doi: 10.1016/j.eururo.2022.08.005. Epub 2022 Aug 30.

# CANCER AND BLOOD



50

Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26].

**Yu EY, Piulats JM, Gravis G, Fong PCC, Todenhöfer T, Laguerre B, Arranz JA, Oudard S, Massard C, Heinzlbecker J, Nordquist LT, Carles J, Kolinsky MP, Augustin M, Gurney H, Tafreshi A, Li XT, Qiu P, Poehlein CH, Schloss C, de Bono JS.**

Eur Urol. 2023 Mar;83(3):e87. doi: 10.1016/j.eururo.2022.11.025. Epub 2022 Dec 15.

51

Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial.

**Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, Hu S, Liu Z, Poddubskaya E, Disel U, Akopov A, Dvorkin M, Zheng W, Ma Y, Wang Y, Li S, Yu C, Rivalland G.**

J Thorac Oncol. 2023 Jan;18(1):93-105. doi: 10.1016/j.jtho.2022.09.217. Epub 2022 Sep 29.

52

A systematic review of the role of chemotherapy in retroperitoneal sarcoma by the Australia and New Zealand sarcoma association clinical practice guidelines working party.

**Zhou DD, Connolly EA, Mar J, Lazarakis S, Grimison PS, Connor J, Gyorki DE, Hong AM.**

Cancer Treat Rev. 2023 Nov 25;122:102663. doi: 10.1016/j.ctrv.2023.102663. Online ahead of print.